Prediction of Response to Anticancer Immunotherapy Using Gene Signatures
- 1 July 2013
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (19) , 2369-2371
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer ImmunotherapyJournal of Clinical Oncology, 2013
- Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic MelanomaJournal of Clinical Oncology, 2013
- Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study ResultsJournal of Clinical Oncology, 2013
- Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the Treatment of Metastatic MelanomaClinical Cancer Research, 2011
- An immunologic portrait of cancerJournal of Translational Medicine, 2011
- gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced MelanomaNew England Journal of Medicine, 2011
- Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironmentCurrent Opinion in Immunology, 2011
- Gene-expression profiling in vaccine therapy and immunotherapy for cancerExpert Review of Vaccines, 2010
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 2006
- A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung cancerCancer, 1996